AVONTEC announces today the results of a multicenter, randomized, double-blind, placebo-controlled, intra-individual-comparison phase 2a trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to moderate psoriasis vulgaris Martinsried/Munich, Germany | October 10, 2008 | AVONTEC GmbH, a privately held bio-pharmaceutical company dedicated to the development of novel therapies for chronic inflammatory diseases, announces today the results of a multicenter, randomized, double-blind, placebo-controlled, intra-individual-comparison phase 2a trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to moderate psoriasis vulgaris. The phase IIa study enrolled 60 male outpatients with mild-to-moderate psoriasis vulgaris and compared 2% AVT-02 UE ointment with...
[read full story]
Your Web Site
